发明名称 |
SELECTIVE TARGETING OF TUMOR VASCULATURE USING ANTIBODY MOLECULES |
摘要 |
The present invention relates to selectively targeting tumoral vasculature in vivo using a human recombinant scFv, L19, to the angiogenesis marker ED-B domain of fibronectin. In preferred embodiments, a complete human IgG1 is employed having the variable regions of L19. In other embodiments is employed a mini-immunoglobulin generated by fusing the scFv L19 to the constant CH4 domain of a secretory IgE isoform that naturally contains a cysteine in its COOH terminal and which forms a covalently linked dimer. Different in vivo behaviour of the antibody formats is exploitable for different diagnostic and/or therapeutic purposes, depending on clinical needs and disease. The antibody molecules may be labelled as described. |
申请公布号 |
PL374386(A1) |
申请公布日期 |
2005.10.17 |
申请号 |
PL20030374386 |
申请日期 |
2003.03.11 |
申请人 |
PHILOGEN SPA.;SCHERING AG |
发明人 |
BORSI LAURA;CARNEMOLLA BARBARA;BALZA ENRICA;CASTELLANI PATRIZIA;ZARDI LUCIANO;FRIEBE MATTHIAS;HILGER CHRISTOPH-STEPHAN |
分类号 |
C12N15/09;A61K38/00;A61K39/395;A61K51/10;A61P9/00;A61P35/00;A61P43/00;C07K16/18;C07K16/44;C07K19/00;C12N1/15;C12N1/19;C12N1/21;C12N5/10;C12N15/13;C12P21/00 |
主分类号 |
C12N15/09 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|